Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Gene Mutation”

226 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 226 results

Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Not applicableStudy completedNCT04961619
What this trial is testing

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Who this might be right for
Melanoma
Novartis Pharmaceuticals 39
Early research (Phase 1)Study completedNCT02608034
What this trial is testing

Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Genentech, Inc. 32
Early research (Phase 1)Study completedNCT01877811
What this trial is testing

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

Who this might be right for
Solid Tumors
Hoffmann-La Roche 143
Testing effectiveness (Phase 2)Active Not RecruitingNCT02231775
What this trial is testing

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Who this might be right for
Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7
M.D. Anderson Cancer Center 58
Testing effectiveness (Phase 2)Study completedNCT01336634
What this trial is testing

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Who this might be right for
Cancer
Novartis Pharmaceuticals 177
Testing effectiveness (Phase 2)Ended earlyNCT02052193
What this trial is testing

Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study

Who this might be right for
Metastatic Melanoma (Carrying BRAF V600 Mutation)
University Hospital Tuebingen 8
Not applicableStudy completedNCT02827565
What this trial is testing

Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Institut de Cancérologie de Lorraine 30
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556
What this trial is testing

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Who this might be right for
MelanomaMalignant Melanoma
ImmVira Pharma Co. Ltd 68
Early research (Phase 1)Ended earlyNCT01940809
What this trial is testing

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Who this might be right for
BRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more
National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044
What this trial is testing

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Who this might be right for
Melanoma
Pierre Fabre Medicament 815
Testing effectiveness (Phase 2)UnknownNCT05641493
What this trial is testing

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Henlius Biotech 49
Not applicableEnded earlyNCT01280643
What this trial is testing

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Fox Chase Cancer Center 3
Testing effectiveness (Phase 2)UnknownNCT05528406
What this trial is testing

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)Study completedNCT02631447
What this trial is testing

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Who this might be right for
Metastatic Melanoma
Fondazione Melanoma Onlus 251
Testing effectiveness (Phase 2)Active Not RecruitingNCT04238624
What this trial is testing

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerThyroid CancerBRAF Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT01677741
What this trial is testing

Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

Who this might be right for
Neoplasms, Brain
Novartis Pharmaceuticals 85
Early research (Phase 1)Temporarily pausedNCT01841463
What this trial is testing

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Who this might be right for
Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Piramal Enterprises Limited 100
Testing effectiveness (Phase 2)Study completedNCT00936221
What this trial is testing

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Who this might be right for
Melanoma
AstraZeneca 385
Testing effectiveness (Phase 2)Study completedNCT03915951
What this trial is testing

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 98
Load More Results